Ildong Pharmaceutical is an established and respected name in South Korea’s pharmaceutical industry. They specialize in developing, manufacturing, and supplying pharmaceutical products.
Ildong Pharmaceutical’s researchers and scientists use state-of-art laboratories and equipment to develop new drugs to battle against resistant bacteria, malignant tumours, Alzheimer’s disease, obesity, and ageing. They are well known for their capacity in the development of raw vitamins, probiotics, and antimicrobials.
Ildong Pharmaceutical has developed a number of power brands such as Biovita, the first commercial lactobacillus product to be introduced in South Korea, and Aronamin, a lineup of popular multivitamins. The company also works with global pharmaceutical companies to manufacture original prescription drugs and utilizes its internal synthesis capacity to manufacture a wide variety of generic prescription drugs.
Ildong Pharmaceutical is currently expanding into functional health food, medical device, cosmetic, and beverage industries and evolving into a total healthcare company of global proportions.
Despite its ageing population and growing need for healthcare, South Korea had just 2.6 doctors per 1,000 inhabitants in 2022, one of the lowest numbers among developed nations. To deal…
The latest pharma and healthcare news from APAC, including Celltrion’s plans to sell its Takeda portfolio to CBC; reforms to the South Korean national insurance system that may lead to…
Global medtech giant Medtronic is hoping that its latest acquisition – EOFlow, a South Korean wearable insulin patch maker – will enhance its competitiveness in the global diabetes market. …
A roundup of some of the most important recent stories from the burgeoning South Korean pharma and biotech industry, including a government plan to expand collaboration with the global innovation…
As big pharma continues to sharpen its focus on R&D by outsourcing other elements of the supply chain, including manufacturing, CDMOs have thrived. Samsung Biologics, one of the world’s top…
Korean biotech SK Bioscience, known for bringing forward the first South Korean-developed COVID-19 vaccine, is pursuing its beyond-COVID growth strategy with a new green light for its SKYCellflu vaccine. The…
After launching the first Korean COVID-19 vaccine, SKYCovione, SK Bioscience is preparing for its next big milestone, a US subsidiary, with the appointment of two new executives who are already…
SK Bioscience’s announcement that the first batch of its domestically developed COVID vaccine has been shipped may mark a significant milestone in South Korea’s journey towards greater vaccine self-sufficiency. …
ExoCoBio’s CEO, Byong Seung Cho, went from biotech venture capital to setting up ExoCoBio, a company whose core technology is based on adipose stem-cell derived exosomes for regenerative medicine and…
South Korea has carved a place for itself as a dominant player in the global pharma and med-tech manufacturing industry with national companies Samsung Biologics and Celltrion leading the way.…
After a dynamic two years as CEO of Samsung Biologics, John Rim highlights some of the fundamentals behind the company’s rapid growth as a CDMO, including the creation of huge…
Stephen Yoo highlights the pioneering work that STCube Pharmaceuticals – a US subsidiary of Korean firm STCube – is undertaking in the immuno-oncology field, its three technology platforms, partnership approach,…
See our Cookie Privacy Policy Here
